Roche Holding AG Net Income 2012-2025 | RHHBY
Roche Holding AG annual/quarterly net income history and growth rate from 2012 to 2025. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
- Roche Holding AG net income for the quarter ending December 31, 2025 was $0M, a 0% increase year-over-year.
- Roche Holding AG net income for the twelve months ending December 31, 2025 was $0M, a 0% increase year-over-year.
- Roche Holding AG annual net income for 2025 was $15.546B, a 65.35% increase from 2024.
- Roche Holding AG annual net income for 2024 was $9.402B, a 26.59% decline from 2023.
- Roche Holding AG annual net income for 2023 was $12.808B, a 1.6% decline from 2022.
|
Roche Holding AG Annual Net Income (Millions of US $) |
|
|---|---|
| 2025 | $15,546 |
| 2024 | $9,402 |
| 2023 | $12,808 |
| 2022 | $13,016 |
| 2021 | $15,241 |
| 2020 | $15,247 |
| 2019 | $13,585 |
| 2018 | $10,735 |
| 2017 | $8,774 |
| 2016 | $9,723 |
| 2015 | $9,224 |
| 2014 | $10,212 |
| 2013 | $12,052 |
| 2012 | $10,179 |
| 2011 | $10,807 |
|
Roche Holding AG Quarterly Net Income (Millions of US $) |
|
|---|---|
| 2025-12-31 | |
| 2025-06-30 | |
| 2024-12-31 | |
| 2024-06-30 | |
| 2023-12-31 | |
| 2023-06-30 | |
| 2022-12-31 | |
| 2022-06-30 | |
| 2021-12-31 | |
| 2021-06-30 | |
| 2020-12-31 | |
| 2020-06-30 | |
| 2019-12-31 | |
| 2019-06-30 | |
| 2018-12-31 | |
| 2018-06-30 | |
| 2017-12-31 | |
| 2017-06-30 | |
| 2016-12-31 | |
| 2016-06-30 | |
| 2015-12-31 | |
| 2015-06-30 | |
| 2014-12-31 | |
| 2014-06-30 | |
| 2013-12-31 | |
| 2013-06-30 | |
| 2012-12-31 | |
| 2012-06-30 | |
| 2011-12-31 | |
| 2011-06-30 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $318.782B | $76.450B |
| Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |